Brexafemme (ibrexafungerp) — United Healthcare
vulvovaginal candidiasis (VVC)
Preferred products
- fluconazole
Initial criteria
- Diagnosis of vulvovaginal candidiasis (VVC)
- AND One of the following:
- — Confirmed azole resistance demonstrated by culture and susceptibility testing
- OR Both of the following:
- — Other causes (including but not limited to bacterial vaginosis or trichomoniasis) have been ruled out
- AND — Failure of a 7-day course of oral fluconazole therapy defined as 100-mg, 150-mg, or 200-mg taken orally every third day for a total of 3 doses (days 1, 4, and 7) for the current episode of VVC
- AND Prescribed by or in consultation with one of the following:
- — Infectious disease physician
- — Obstetrician/Gynecologist
Approval duration
3 months